Truist raised the firm’s price target on Fresenius Medical (FMS) to $25 from $23 and keeps a Hold rating on the shares as ...

The J.P. Morgan Healthcare Conference attracts thousands of attendees each year from the provider, insurance, digital health ...

Learn more about whether Cardinal Health, Inc. or Fresenius Medical Care AG is a better investment based on AAII's A+ ...

Fresenius Medical Care AG & Co KGaA is a Germany-based holding and kidney dialysis company, operating in the fields of dialysis products and dialysis services. Its dialysis business is vertically ...

Fresenius Medical Care (NYSE:FMS – Free Report) had its price target lifted by Truist Financial from $23.00 to $25.00 in a research note published on Monday,Benzinga reports. Truist Financial ...

Fresenius is a strong buy with a 60% Return on Revenue potential in the next 3 years, driven by earnings growth and strategic ...

In recent trading, shares of Fresenius Medical Care AG (Symbol: FMS) have crossed above the average analyst 12-month target price of $22.50, changing hands for $22.81/share. When a stock reaches ...

Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® approved by Health Canada for both subcutaneous and intravenous ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Here are three stocks with buy rank and strong income characteristics for investors to consider today, January 7: Primo ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Here are three stocks with buy rank and strong value characteristics for investors to consider today, January 7: Fresenius ...